Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions Thursday July ii

ThPeB7333 Retrospective analysis of sociodemographic and
clinical characteristics associated with cardiac
procedures among HIV-positive individuals on
antiretroviral therapy from 1992-2001
P KA Braitstein, B Yip, IS G Montaner, A Levy,
J Joseph, FM Kiely, M V O'Shaughnessy, R S Hogg
(Canada)
ThPeB7334 Evaluation of glucocorticoid reserves in children
with HIV infection
R H Merchant, A Sharma, J Oswal, P Menon
(India)
ThPeB7335 Megace and Oxandrolone together: impact of
increasing both fat and lean body mass on
quality of life in HIV/AIDS
M D Mwamburi, J Gerrior, E Skully, S Sabouri,
C Wanke (United States)
ThPeB7336 Human adipocytes and pre-adipocytes are not
permissive to HIV-1 infection in vitro
CL Tremblay, F Giguel, D Olson, E Rosen,
M S Hirsch, S Grinspoon (United States)
ThPeB7337 Changes in sexual behaviour due to body image
in People Living with HIV (PLWH's): a pilot study
M C Bello (Venezuela)
ThPeB7338 Body composition, visceral fat and bone mineral
density: a comparison of HIV infected and noninfected women
B Smith, J Raper, M Weaver, B Gower, G Hunter,
L Randazza, R Weinsier, M Saag (United States)
ThPeB7339 The effects of a diet and exercise weight loss
program in obese HIV-infected women
ES Engelso n D Agin, S Kenya, Q He, B Luty,
G Werber-Zion, J Wang, S B Heymsfield, J B Albu,
D P Kotler (United States)
ThPeB734o Does lipodystrophy affect quality of life?
G Orlando', G Guaraldi', R Murri', A Wu2,
G Nardini', B Beghetto', G K Sterrantino',
S Sbaragli', M Borderi', S Talb', C Grosso',
C Erba', A M Cattelan', A Antinori', R Esposito'
('Italy; 2United States)
ThPeB7341 The impact of HIV-associated adipose
redistribution syndrome on psychological wellbeing and quality of life: a cross-sectional survey
MA Testa, M Thompson, R R Turner,
N Muurahainen, J M Gertner (United States)
ThPeB7342 The triglyceride-lowering effect of omega-3 fatty
acids in HIV-infected patients on HAART
D Peabody, V Remple, T Green, A Kalmar,
J Frohelich, J DeWet, D Burdge (Canada)
ThPeB7343 Differences in endothelial function in HIV-infected
patients with or without HIV protease inhibitor
regimens and in HIV-negative controls
B R Cotter, 0 L Kwan, JS Currier, A N DeMaria,
F] Torriani (United States)
ThPeB7344 The heparin-releasable lipoprotein and hepatic
lipase activity in relation to the protease inhibitor
plasma level in HIV-infected patients with
lipodystrophy/dyslipidemia
T Buhk, 0 Degen, I van Lunzen, H ]Stellbrink,
U Beisiegel (Germany)
ThPeB7345 Effect of highly active antiretroviral therapy
(HAART) on body composition, energy
expenditure, caloric intake and its relation to
changes in viral load in patients with AIDSrelated wasting syndrome
L Z L Ldpez Zaragoza ]L, S E B Salgado-Enriquez
BL, T H] Tovar-Hirashima j, M G P Milke-Garcfa
MP, S R L Soto-Ramfrez LE, CM ]Calva-Mercado

J, PR S Ponce de Ledn-Rosales S, SM ] SierraMadero I (Mexico)

ThPeB7346 A randomized, double-blind, placebo-controlled,
comparative study on the effects of metformin or
gemfibrozil on markers of fibrinolysis and
increased cardiovascular risk in HIV-infected
patients with lipodystrophy
P Domingo, E Martinez, J B Perez Cuevas,
JA ArroVo, A Milinkovic, I Conget, MA Sambeat,
M Borrell, J Fontcuberta, J M Gatell (Spain)
ThPeB7347 Bone mineral density (BMD) and body shape
abnormalities (BSA) in HIV patients who have
been on stable first line treatment for prolonged
periods
M Torralba, S A Azriel, R R Rubio, F Pulido,
E Jodar, F Hawkins, J R Costa, A Palacio (Spain)
ThPeB7348 HAART and diabetes mellitus
R Marques C Rodrigues, M H Gomes, V Baldaia,
N Ribeiro, I Neves, A Mota Miranda (Portugal)
ThPeB7349 Increased levels of Plasminogen Activator
Inhibitor 1 in HIV patients with insulin resistance
A Bocassi, G de Larrafiaqa, L Puga, B Alonso,
J Benetucci (Argentina)
ThPeB735o Thrombotic risk markers in HIV patients with
lipodystrophy
G de Larranaqa, A Bocassi, L Puga, N Gomez,
S Morua, B Alonso, J Benetucci (Argentina)
ThPeB7351 Methods for quantifying insulin resistance in HIVinfected patients
G Beatty, W Chu, FAbbasi, M Khalili, J Koch,
A Rosen, J Schmidt, J Stansell, G M Reaven
(United States)
ThPeB7352 Recombinant human growth hormone therapy in
HAART patients with HIV-associated wasting
(HAW) H Jaeger, H Knechten, A Moll, L Weitner,
H Fischer, K Schmitt-Rau (Germany)
ThPeB7353 Short term impact of lipid lowering drugs
(fibrates and statins) on lipid plasma levels in
HAART-treated patients. Aquitaine Cohort,
France, 1999-2001
F Bonnet E Balestre, R Thidbaut, P Mercid,
M Dupon, D Malvy, P Morlat, F Dabis (France)
ThPeB7354 Metabolic and body composition changes in
patients switching from a protease inhibitorcontaining regimen to Abacavir (ABC), Efavirenz
(EFV) or Nevirapine (NVP). Twelve-month results
of a randomized study (LIPNEFA)
C Fisac, E Fumero, M Crespo, B Roson, R Burgos,
E Ferrer, N Virgili, E Ribera, J M Gatell,
D Podzamczer (Spain)
ThPeB7355 Risk of lipodystrophy in HIV--infected patients
receiving highly active antiretroviral therapy not
containing protease inhibitors: a prospective
cohort study
E Martinez, A Milinkovic, M Garcia, J B PerezCuevas, I L Blanco, I Murillas, M Lonca, I Mallolas,
I M Gatell (Spain)
ThPeB7356 Insulin sensitivity and body composition in obese
H IV+ women
J B Albu, ES Engelson, S Kenya, A Kovera,
M Littschwager, M Wainright, D P Kotler
(United States)
ThPeB7357 Studies of subcutaneous adipose tissue (SAT) in
HIV+ subjects with and without lipodystrophy
I ]ohnson, B Albu, E S Engelson, G Ionescu,
I Sheikhan, D P Kotler (United States)
ThPeB7358 Comparison of bioimpedance analysis and
anthropometrics in the estimate of truncal fat
Q He, IWang, ES Engelson, DP Kotler

(United States)

Thursday

XIV International AIDS Conference BARCELONA - JULY 7-12

225